Continuing education credit for physicians, pharmacists, and case managers is available as listed below. Newest supplements are listed first. All supplements in PDF.
If you need Acrobat Reader to access PDFs,
you can download it from Adobe.
 | Growth Hormone Treatment: Evidence, Practice, and Emerging IssuesThe effects of growth hormone deficiency (GHD) on the stature and maturation of children are well established. Recombinant DNA technology now allows the production and use of recombinant growth hormone to correct those effects without the limitations and safety concerns associated with growth hormone (GH) derived from pituitary tissue. GH therapy is also gaining acceptance for treating idiopathic short stature (ISS) in children whose growth rate is subnormal but who have no GH deficiency or other endocrine abnormality. The normal aging process in adults is accompanied by a substantial decline in GH, and recent research supports the damaging effects of GHD associated with atherosclerosis and osteoporosis. Other research is investigating GHD as a factor in chronic fibromyalgia and AIDS. This continuing education program provides information on the current status of GH therapy for children and adults so that managed care professionals can better understand the diagnostic and treatment algorithms and the scientific rationale for expanded use of GH therapy.Highlights:
Accreditation and designation Physicians: This educational activity is approved for 1.0 AMA PRA Category 1 credit™. Pharmacists: This educational activity is approved for 1 contact hour (0.10 CEU). ACPE UPN 812-000-09-002-H01-P. Nurses: This educational activity is approved for 1 contact hour (0.10 CEU). Case Managers: An application has been submitted to the Commission for Case Manager Certification (CCMC) for 1.0 clock hour. Release Date: Aug.15, 2009; Expiration Date: Aug.15, 2010. For further information, contact The Chatham Institute at (973) 701-2515. |
 | Respiratory Synctial Virus (RSV): Prevention Strategies and the Appropriate Identification of Vulnerable PopulationsRespiratory syncytial virus (RSV) infection of the lower respiratory tract is the leading cause of hospitalization of infants younger than 1 year of age in the United States. Up to 126,000 infants are hospitalized each year for bronchiolitis or pneumonia, and close to 20 percent of these are premature infants. RSV hospitalization is costly, amounting to more than $5,000 a day for an infant in need of respiratory assistance. RSV infection is also common among the elderly and immunocompromised individuals, and accounts for about 180,000 hospital admissions each year at a cost exceeding $1 billion. Immunoprophylaxis along with common-sense hygiene measures are key to protecting high-risk populations. This supplement presents up-to-date information on the seasonal variability of RSV, prevention strategies, therapeutic approaches, and managed care considerations to better manage RSV. This supplement is based on an RSV Expert Panel held in Chicago, Aug. 18, 2008. Highlights:
|
